Premium
Low rates of transfusion‐transmitted infection screening in chronically transfused adults with sickle cell disease
Author(s) -
Chidambaram Vignesh,
Jones Jennifer M.,
Lokhandwala Parvez M.,
Bloch Evan M.,
Lanzkron Sophie,
Stewart Rosalyn,
Pecker Lydia H.
Publication year - 2021
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.16547
Subject(s) - medicine , vaccination , hepatitis b , hepatitis b virus , population , immunology , blood transfusion , virus , environmental health
Background Adults with sickle cell disease (SCD) on chronic transfusion therapy are exposed to a large volume of blood products, thus increasing their risk of transfusion‐associated human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV). Methods We performed a systematic chart review of chronically transfused SCD subjects at the Johns Hopkins Sickle Cell Center for Adults between October 2014 and September 2019 to determine our Center's adherence to the 2014 National Heart, Lung and Blood Institute (NHLBI) SCD guidelines for annual screening for Transfusion Transmitted infections (TTI) and assessed HBV immunity and HBV vaccination rates. Results The study included 85 subjects with a median age of 34 years (23–63); 52% were female. No subject received annual screening; 68 subjects (80%) were screened for HIV, 60 subjects (71%) for HCV and 53 subjects (62%) for HBV infections at least once in the study period. Of those screened, one patient was newly diagnosed with HCV infection, and none with HIV or HBV infection. Among 31 subjects tested for anti‐Hepatitis B surface antibody, 16 subjects (52%) tested negative. Nineteen (20%) subjects had HBV vaccination documented. Conclusions Low adherence to the NHLBI TTI screening guidelines, especially for HBV, highlights the resource intensiveness of this patient population. The low rates of anti‐Hepatitis B surface antibody positivity highlight the need to confirm vaccination, provide boosters as indicated, and investigate the adults with SCD's immune response to HBV vaccination.